Trial Profile
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 08 Oct 2022 Status changed from active, no longer recruiting to completed.
- 25 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Dec 2022.
- 01 Jul 2021 Planned primary completion date changed from 31 Dec 2020 to 30 Jun 2022.